Zacks.com on MSN17h
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average.
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Money Morning1d
Teva Smashes $20 Resistance: Bullish Momentum Builds After UC Drug Success
Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...
Teva price target raised to $28 from $26 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares. After Phase 2 ...
globes.co.il13h
Teva share price at 6-year high after trial results
The dramatic rise is another peak in Teva's recovery over the past year and rewards investors after a long period of ...
FierceBiotech1d
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
Teva price target raised to $28 from $25 at Barclays
Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The ...
Teva, Sanofi Say IBD Treatment Achieved Higher Remission at Trial
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...